Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Metastatic
Is there any data to use PIK3CA directed agents in mutated metastatic triple negative breast cancer?
Related Questions
How would you manage new symptomatic brain metastases (10-15) in a young woman with HER2+ metastatic breast cancer?
In patients with both ESR1 and PIK3CA mutations who have progressed on AI+CDK4/6 inhibitor, how are you deciding the treatment/sequence of next-line therapies?
How do you define PIK3CA/AKT/PTEN alteration for capivasertib use?
Are you comfortable combining palliative radiotherapy with capivasertib/fulvestrant?
What is the current paradigm for breast cancer diagnosed with isolated metastases prior to initial treatment?
What are your top takeaways from SABCS 2023?
What initial treatment would you offer a patient with metastatic triple negative breast cancer with somatic BRCA1/2 mutation, CPS <10?
What is your experience and treatment efficacy of tucatinib if used after enhertu in metastatic breast cancer?
Would you offer capivasertib+fulvestrant in a patient with metastatic HR+ HER2 negative breast cancer with PTEN mutation who has progressed on fulvestrant plus ribociclib?
How do you treat metastatic adenoid cystic carcinoma of breast primary, ER 3%, PR, HER 2 negative with liver only metastasis?
